All News

Presentation of results at the European Association for the Study of Diabetes follows the announcement of topline results in August. For years, researchers and pharmaceutical leaders alike wondered if a diabetes therapy would be shown to have a cardioprotective effect.

Scientists in Spain have identified gene mutations that trigger bone metastasis in breast cancer patients.

While employers will continue to shift healthcare costs to employees, a new report found that the underlying cost growth, which employers would expect if they did not make changes such as raising deductibles or switching carriers, will slow in 2016.

At the recently held NCCN healthcare policy summit in Washington, DC, experts delved into various models being evaluated to reduce healthcare utilization in oncology care.

Healthcare policy makers, payers, medical centers, and patient representatives shared the dais as they discussed The Value Proposition in oncology.

The report included some famous examples of states that had to abandon early IT efforts despite large sums spent

Metastatic melanoma patients treated with pembrolizumab responded better if their T cells had a higher level of Bim expression.

Women bear greater costs related to Alzheimer's disease (AD) compared with men for 2 reasons: they are at greater risk of developing the AD and cost Medicare and Medicaid more, and they are more likely to provide informal, unpaid care to family members with AD.

The company's Prevent program is approved by CDC as meeting standards for obesity prevention counseling as required of payers by the US Prevention Services Task Force.

Robert Califf, MD, current deputy commissioner for medical products and tobacco at the FDA, has been nominated to lead the FDA and take over as commissioner. Margaret Hamburg, MD, stepped down from the position in February after nearly 6 years at the helm.

The report, commissioned by the Community Oncology Alliance, finds that Medicare Part B cancer drug spending rose 123% in 340B hospitals from 2010 to 2013, but only 31% in non-340B hospitals; it fell 5% in community practices in the same period.

Nearly half a billion dollars in Affordable Care Act funding will be awarded to health centers around the country to help them provide primary care services to those who need them most.

The American Society of Clinical Oncology has urged Congress to recognize the impact of barriers to interoperability of electronic health records on patient outcomes.

Thomas R. Insel, MD, leaves the National Institute of Mental Health after setting in motion a series of projects that will pair personalized medicine with improved detection and prevention of major mental health disorders.

The American Journal of Managed Care spoke with Bruce J. Gould, MD, medical director of Northwest Georgia Oncology Centers on the impact of the 340B drug pricing program on private oncology practices.

Researchers analyzed patient records from a 25-year period and found risks increased with higher doses and longer periods of treatment.

The study, published in the journal Cancer, found that non-biological factors are as important as biological variables in shaping outcomes in young patients with leukemia.

Supporters say the bill would bring choice and dignity to those suffering, while opponents say the poor will be pressured by family members and heirs to take their lives because healthcare is too expensive.

Regulatory filings with the FDA are expected before the end of the year.

Unaccounted for social and clinical characteristics of a hospital's patient population explain nearly half of the difference in readmission rates between the best and the worst performing hospitals when it comes to Medicare penalties for hospital readmission rates.

Healthcare policy experts gathered in Washington, DC, to discuss access, cost, and the definition of value in oncology care.

The American public's perennially low opinion of the pharmaceutical industry has gotten even lower, and it seems unlikely that public opinion will gain much ground over the next year.

People with insurance have significantly higher probabilities of being diagnosed for diabetes, hypercholesterolemia, and hypertension than people without insurance.

The top stories in managed care this week include value-based pricing of the new PCSK9 inhibitors, CMS unveiled a new health equity plan for Medicare, and the American Medical Association released analyses on proposed health insurance mergers.

Democratic president hopeful Bernie Sanders took aim at the pharmaceutical industry with a new bill that would provide the government with negotiating power, allow the import of lower-cost drugs from Canada, and requires reporting of information that affects drug pricing.

CVS Health says narrow networks improve medication adherence in patients with chronic diseases.

An abstract presented at the 16th World Conference on Lung Cancer presented results from a study that monitored irAEs resulting from treatment with immune checkpoint inhibitors.

Avoidable risk factors to health are taking a growing toll on global health, according to an analysis of 79 risks in 188 countries. The results were published in The Lancet.

Treatment for high blood pressure should be more aggressive with a target lower than commonly recommended by guidelines, according to a study from the National Institutes of Health.

Although a new report from The Commonwealth Fund raised concerns about the competition of Medicare Advantage (MA) programs available across the country, a new analysis from Avalere Health found that there has been a growing number of MA plan options for consumers.